Generation of highly activated, antigen-specific tumor-infiltrating CD8⁺ T cells induced by a novel T cell-targeted immunotherapy.

ABSTRACT: The induction of tumor-targeted, cytotoxic T lymphocytes has been recognized as a key component to successful immunotherapy. DPX-based treatment was previously shown to effectively recruit activated CD8⁺ T cells to the tumor. Herein, we analyze the unique phenotype of the CD8⁺ T cells recruited into the tumor in response to DPX-based therapy, and how combination with checkpoint inhibitors impacts T cell response. C3-tumor-bearing mice were treated with cyclophosphamide (CPA) for seven continuous days every other week, followed by DPX treatment along with anti-CTLA-4 and/or anti-PD-1. Efficacy, immunogenicity, and CD8⁺ T cells tumor infiltration were assessed. The expression of various markers, including checkpoint markers, peptide specificity, and prolifera

SUBMITTER: Vila-Leahey A 

PROVIDER: S-EPMC7458631 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature